Index
By TNW
About Index
Trending news
Analyze
Pricing
Sign up or sign in
AbbVie
Work at AbbVie?
Add yourself to this profile
2977
AbbVie
AbbVie's official global Twitter feed featuring news and updates managed by our global newsroom. Review our Twitter guidelines here on our site
Edit Profile
abbvie.com
Technology
>
Biotechnology
Health Care
>
Medical
>
Pharmaceuticals
B2b
Founded in
2013
More info
Elsewhere
Also headquartered in Chicago
Motorola
Boeing
Groupon
Accenture
Dyson
Walgreens
GrubHub
United
Signal
The Onion
Companies in the same industry
Synedgen
Perrigo Careers
TetraGenetics
Thermosome
eXIthera Pharmaceuticals
Verona Pharma Plc
3D Bio Holdings
Cyclica Inc.
Prexton Therapeutics SA
Alimera Sciences
Alexa global traffic share
Twitter followers
Overview
Investments
4
Acquisitions
1
Apps
5
Add info
Employees
Team size
10000+
Locations
HQ
Chicago
,
United States
Headquarters
Xconomy
More Job Cuts at Infinity As AbbVie Sends Back Blood Cancer Drug
Health
The Motley Fool
Better Buy: Merck & Co. Inc. vs. AbbVie
Stock markets
Health
The Motley Fool
Better Buy: AbbVie Inc. vs. Johnson & Johnson
The Motley Fool
AbbVie's Rova-T Update at ASCO: Good or Bad?
Health
The Motley Fool
3 Reasons to Buy AbbVie Inc.
The Motley Fool
Is AbbVie's Stock Too Risky?
The Motley Fool
3 Reasons AbbVie's and Biogen's Latest MS Drug Might Flop
The Motley Fool
A Heavy Hitter Just Stepped Up to the Cystic Fibrosis Plate
The Motley Fool
Why June Could Be a Big Month for AbbVie Investors
via
Bloomberg
,
TechCrunch
Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund
Funding
Health
The Motley Fool
,
Silicon Beat
Sanofi's Bid for Medivation Is Too Low
$5,800,000,000
TechCrunch
,
Xconomy
,
Business Insider
, +1
AbbVie acquiring cancer drug startup StemcenTrx for $5.8 billion
Health
Funding
Strategy
The Motley Fool
Better Buy: Pfizer Inc. vs. AbbVie
Stock markets
Health
The Motley Fool
AbbVie's Venclexta Notches FDA Win, But Investors Might Want To Temper Enthusiasm
The Motley Fool
Better Buy: AbbVie vs. Johnson & Johnson
The Motley Fool
AstraZeneca or AbbVie: Which Is Better for Dividend Growth Investors?
The Motley Fool
AbbVie Inc.'s Big Win Over Gilead Sciences Wasn't in Hepatitis C
The Motley Fool
Better Buy: AbbVie Inc. vs. Eli Lilly
Health
Earnings
The Motley Fool
Instant Analysis: Regeneron Pharmaceuticals and Sanofi's Experimental Drug Bests an AbbVie Blockbuster
The Motley Fool
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
Motorola
Boeing
Groupon
Accenture
Dyson
Walgreens
GrubHub
United
Signal
The Onion
Synedgen
Perrigo Careers
TetraGenetics
Thermosome
Cyclica Inc.
Alimera Sciences